Predicting Adjuvant Chemotherapy Response in Lung Cancer
Predicting Adjuvant Chemotherapy Response in Lung Cancer
批准号:
8225350
负责人:
Yang Xie
金额:
$33.43万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-02-28
关键词:
AccountingAdjuvant ChemotherapyAdoptedAdverse effectsArea Under CurveCancer CenterCancer PatientCause of DeathCessation of lifeChemotherapy-Oncologic ProcedureClinicalClinical DataClinical ResearchCopy Number PolymorphismDNA copy numberDataData AnalysesData SetDecision MakingDimensionsDisease-Free SurvivalEpidemiologyEvaluationExcisionGenesGenetic PolymorphismGoalsHistologyIndividualJointsKnowledgeLeadLiteratureLungMalignant NeoplasmsMalignant neoplasm of lungMedical OncologyMedicineMessenger RNAMethodologyMethodsModelingMolecular ProfilingNon-Small-Cell Lung CarcinomaOutcomePathological StagingPathologyPatientsPerformanceReceiver Operating CharacteristicsRecurrenceResearchResectedResistanceRiskSamplingSelection for TreatmentsStagingSubgroupSurvival RateTexasTimeTissue BankingTissue BanksTranslational ResearchTranslationsTumor-DerivedUnited StatesUniversitiesWeightWomananticancer researchbasecancer therapychemotherapyclinical decision-makingclinical epidemiologyclinical practicecohortdrug sensitivityepidemiologic datafollow-upgenetic epidemiologygenome-wideimprovedmRNA Expressionmennovelpre-clinicalprogramsprotein expressionpublic health relevancerandomized trialresponsestandard of care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Project Summary: Lung Cancer is the leading cause of death from cancer in the United States. Adjuvant chemotherapy is increasingly used as the standard of care for patients with resected Non-Small-Cell Lung Cancer (NSCLC). However, such treatment is also associated with serious adverse effects. A large amount of drug sensitivity data, as well as clinical, epidemiology and genome-wide molecular profiling data have been collected by The University of Texas Specialized Program in Research Excellence (UT SPORE) in Lung Cancer to develop personalized cancer treatments. However, the integration and translation of these massive data to scientific knowledge and clinical usage has become a bottleneck of current cancer research. This study aims at tackling this problem and building a comprehensive prediction model of response to adjuvant chemotherapy in lung cancer. We will use the existing preclinical, clinical and epidemiology data to develop a comprehensive prediction model. We will collaborate with UT SPORE in Lung Cancer to collect new data on an independent patient cohort to validate the model. The specific aims of this study are: (1) To develop and compare predictive signatures from individual molecular profiling datasets including mRNA expression, protein expression, copy number variation and germline polymorphism data. (2) To build a comprehensive prediction model of response to adjuvant chemotherapy by integrating predictive molecular signatures and clinical information. (3) To validate and characterize the comprehensive prediction model using an independent patient cohort. This project assembles an outstanding research team with complementary expertise in quantitative research, clinical research, translational research, pathology and genetic epidemiology, and is dedicated to improving lung cancer treatments. If implemented successfully, this project will have substantial impact on lung cancer clinical practice and translational cancer research.
PUBLIC HEALTH RELEVANCE: Project Narrative. The goal of this proposal is to develop a comprehensive prediction model for adjuvant chemotherapy response to assist in the clinical decision of whether an individual lung cancer patient should receive adjuvant chemotherapy or not.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel computational approaches to predict drug response and combination effects
-
批准号:10378536
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2020
-
负责人:Yang Xie
-
依托单位:
Novel computational approaches to predict drug response and combination effects
-
批准号:10594584
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2020
-
负责人:Yang Xie
-
依托单位:
Novel computational approaches to predict drug response and combination effects
-
批准号:10133094
-
项目类别:
-
资助金额:$40.95万
-
财政年份:2020
-
负责人:Yang Xie
-
依托单位:
Integrative Analysis to Identify Regulation Targets of RNA-Binding Proteins
-
批准号:9104615
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2016
-
负责人:Yang Xie
-
依托单位:
Integrative Analysis to Identify Regulation Targets of RNA-Binding Proteins
-
批准号:9243275
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2016
-
负责人:Yang Xie
-
依托单位:
Data Science Shared Resource
-
批准号:10478027
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Data Science Shared Resource
-
批准号:10170624
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Data Science Shared Resource
-
批准号:10693235
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Predicting Adjuvant Chemotherapy Response in Lung Cancer
-
批准号:8617729
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Predicting Adjuvant Chemotherapy Response in Lung Cancer
-
批准号:8444696
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Predicting Adjuvant Chemotherapy Response in Lung Cancer
-
批准号:8132363
-
项目类别:
-
资助金额:$33.27万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Bioinformatics Shared Resource
-
批准号:10260740
-
项目类别:
-
资助金额:$9.27万
-
财政年份:2010
-
负责人:Yang Xie
-
依托单位:
Data Science Core (Data Analytics, Biostatistics and Database)
-
批准号:10701022
-
项目类别:
-
资助金额:$23.94万
-
财政年份:1997
-
负责人:Yang Xie
-
依托单位:
Data Science Core (Data Analytics, Biostatistics and Database)
-
批准号:10203841
-
项目类别:
-
资助金额:$24.88万
-
财政年份:1997
-
负责人:Yang Xie
-
依托单位:
Biostatistics and Bioinformatics Core
-
批准号:8747071
-
项目类别:
-
资助金额:$27.81万
-
财政年份:1996
-
负责人:Yang Xie
-
依托单位:
Biostatistics and Bioinformatics Core
-
批准号:9125752
-
项目类别:
-
资助金额:$27.59万
-
财政年份:--
-
负责人:Yang Xie
-
依托单位:
Data Science Core (Data Analytics, Biostatistics and Database)
-
批准号:10023864
-
项目类别:
-
资助金额:$25.41万
-
财政年份:--
-
负责人:Yang Xie
-
依托单位:
Biostatistics and Bioinformatics Core
-
批准号:9341104
-
项目类别:
-
资助金额:$29.35万
-
财政年份:--
-
负责人:Yang Xie
-
依托单位:
海外基金